Russell P. Rother

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Selexys Pharmaceuticals Corp. operates as a biopharmaceutical company, which focuses on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases. The firm solutions are used to treat vasoocclusion and thrombosis, such as vasoocclusive pain crisis in sickle cell disease and deep venous thrombosis; chronic inflammatory diseases and formation of atherosclerotic plaques. The company was founded by Richard D. Cummings, Richard Alvarez and Rodger P. McEver in 2002 and is headquartered in Oklahoma, OK.

Tetherex Pharmaceuticals Corp. operates as a biopharmaceutical company. It focuses on development of therapeutics for the treatment of thrombosis, inflammation and tumor metastasis across a broad range of severe diseases. The company was founded by Rodger P. McEver and Richard D. Cummings and is headquartered in Oklahoma City, OK.

Gene Technologies Ltd. operated as a molecular diagnostics company. The company was headquartered in Braintree, the United Kingdom.

Moat Biotechnology Corp. is a biopharmaceutical company that focuses on developing vaccines. The company is based in Oklahoma City, OK.